A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax(®)) COVID-19 Vaccination

Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Kore...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyung Yoon, Cho, Jae Yeong, Yoon, Hyun Ju, Choi, Yoo-Duk, Ahn, Youngkeun, Jeong, Myung Ho, Cho, Jeong Gwan, Kim, Kye Hun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424696/
https://www.ncbi.nlm.nih.gov/pubmed/36038960
http://dx.doi.org/10.3346/jkms.2022.37.e265
Descripción
Sumario:Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vaccination complication by Novavax® in Korea.

Ejemplares similares